What's new

Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

Jun 6, 2025 - 11:00
 0
Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised
Read More

Tags:

Previous Article

PSUSA/00001842/202410

Next Article

Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab...

Related Posts

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025  0

On-boarding of users to Substance, Product, Organisatio...

Jun 6, 2025  0

Veterinary medicines European public assessment report (EPAR): Hepizovac, epizootic haemorrhagic disease vaccine (inactivated), Status: Authorised

Veterinary medicines European public assessment report ...

Jun 2, 2025  0